CYP3A4 and CYP3A5 Genotyping Recommendations : A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase
Copyright © 2023 Association for Molecular Pathology and American Society for Investigative Pathology. All rights reserved..
The goals of the Association for Molecular Pathology Clinical Practice Committee's Pharmacogenomics (PGx) Working Group are to define the key attributes of pharmacogenetic alleles recommended for clinical testing and a minimum set of variants that should be included in clinical PGx genotyping assays. This document series provides recommendations for a minimum panel of variant alleles (tier 1) and an extended panel of variant alleles (tier 2) that will aid clinical laboratories when designing assays for PGx testing. The Association for Molecular Pathology PGx Working Group considered functional impact of the variant alleles, allele frequencies in multiethnic populations, the availability of reference materials, and other technical considerations for PGx testing when developing these recommendations. The goal of this Working Group is to promote standardization of PGx gene/allele testing across clinical laboratories. This document will focus on clinical CYP3A4 and CYP3A5 PGx testing that may be applied to all CYP3A4- and CYP3A5-related medications. These recommendations are not to be interpreted as prescriptive but to provide a reference guide.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
The Journal of molecular diagnostics : JMD - 25(2023), 9 vom: 14. Sept., Seite 619-629 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pratt, Victoria M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CYP3A4 protein, human |
|---|
| Anmerkungen: |
Date Completed 22.08.2023 Date Revised 10.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jmoldx.2023.06.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359203051 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359203051 | ||
| 003 | DE-627 | ||
| 005 | 20240210232549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jmoldx.2023.06.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM359203051 | ||
| 035 | |a (NLM)37419245 | ||
| 035 | |a (PII)S1525-1578(23)00136-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pratt, Victoria M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CYP3A4 and CYP3A5 Genotyping Recommendations |b A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.08.2023 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Association for Molecular Pathology and American Society for Investigative Pathology. All rights reserved. | ||
| 520 | |a The goals of the Association for Molecular Pathology Clinical Practice Committee's Pharmacogenomics (PGx) Working Group are to define the key attributes of pharmacogenetic alleles recommended for clinical testing and a minimum set of variants that should be included in clinical PGx genotyping assays. This document series provides recommendations for a minimum panel of variant alleles (tier 1) and an extended panel of variant alleles (tier 2) that will aid clinical laboratories when designing assays for PGx testing. The Association for Molecular Pathology PGx Working Group considered functional impact of the variant alleles, allele frequencies in multiethnic populations, the availability of reference materials, and other technical considerations for PGx testing when developing these recommendations. The goal of this Working Group is to promote standardization of PGx gene/allele testing across clinical laboratories. This document will focus on clinical CYP3A4 and CYP3A5 PGx testing that may be applied to all CYP3A4- and CYP3A5-related medications. These recommendations are not to be interpreted as prescriptive but to provide a reference guide | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Cytochrome P-450 CYP3A |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 650 | 7 | |a CYP3A5 protein, human |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 650 | 7 | |a CYP3A4 protein, human |2 NLM | |
| 650 | 7 | |a EC 1.14.14.55 |2 NLM | |
| 700 | 1 | |a Cavallari, Larisa H |e verfasserin |4 aut | |
| 700 | 1 | |a Fulmer, Makenzie L |e verfasserin |4 aut | |
| 700 | 1 | |a Gaedigk, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Hachad, Houda |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Kalman, Lisa V |e verfasserin |4 aut | |
| 700 | 1 | |a Ly, Reynold C |e verfasserin |4 aut | |
| 700 | 1 | |a Moyer, Ann M |e verfasserin |4 aut | |
| 700 | 1 | |a Scott, Stuart A |e verfasserin |4 aut | |
| 700 | 1 | |a van Schaik, Ron H N |e verfasserin |4 aut | |
| 700 | 1 | |a Whirl-Carrillo, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Weck, Karen E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of molecular diagnostics : JMD |d 1999 |g 25(2023), 9 vom: 14. Sept., Seite 619-629 |w (DE-627)NLM111386683 |x 1943-7811 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:9 |g day:14 |g month:09 |g pages:619-629 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jmoldx.2023.06.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 9 |b 14 |c 09 |h 619-629 | ||